CSPC Group announced that the phase IB/II clinical trial of the SYS6090 injection developed by the Group for the treatment of hepatocellular carcinoma has been officially launched at the first center in China. This product is a class 1 therapeutic biological product. It is a recombinant all-human anti-PD-1 fusion protein with IL-15. Preclinical studies have shown that it can significantly inhibit tumor growth and is safe and well tolerated. Previously, the Group had obtained a drug clinical trial approval notice issued by the State Drug Administration in July 2026.

CSPC Group announced that the phase IB/II clinical trial of the SYS6090 injection developed by the Group for the treatment of hepatocellular carcinoma has been officially launched at the first center in China. This product is a class 1 therapeutic biological product. It is a recombinant all-human anti-PD-1 fusion protein with IL-15. Preclinical studies have shown that it can significantly inhibit tumor growth and is safe and well tolerated. Previously, the Group had obtained a drug clinical trial approval notice issued by the State Drug Administration in July 2026.